ABUS Stock Cash Flow Statements

Arbutus Biopharma Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Arbutus Biopharma Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31

operating activities
net income	2,523,000	-24,526,000	-12,532,000	-19,717,000	-19,796,000	-17,875,000	-19,312,000	-20,104,000	-17,094,000	-16,339,000	-21,932,000	-17,567,000	-14,192,000	-15,765,000	-21,321,000	-19,158,000	-19,387,000	-16,381,000	-17,042,000	-18,755,000	-14,087,000	-13,861,000
non-cash items:
depreciation	11,000	330,000	333,000	336,000	356,000	355,000	359,000	369,000	342,000	334,000	307,000	343,000	383,000	394,000	427,000	447,000	436,000	443,000	487,000	490,000	501,000	500,000	1,521,000
loss on impairment of leasehold improvements and lab equipment	0	2,811,000
stock-based compensation expense	864,000	3,564,000	1,632,000	2,160,000	3,180,000	2,014,000	1,723,000	2,483,000	2,964,000	2,131,000	1,667,000	1,715,000	2,064,000	1,736,000	1,431,000	1,615,000	1,743,000	1,635,000	1,431,000	1,688,000	1,597,000	1,445,000	5,283,000	-2,268,000	2,262,000	1,522,000
change in fair value of contingent consideration	260,000	299,000	1,890,000	344,000	211,000	180,000	227,000	205,000	-636,000	273,000	1,609,000	215,000	208,000	201,000	193,000	856,000	694,000	129,000	125,000	120,000	116,000	112,000	203,000	-506,000	5,000	125,000	-1,690,000	-5,801,000	1,041,000	-848,000	1,162,000	307,000	-1,169,000	1,059,000	1,308,000	8,000	8,000	244,000
non-cash royalty revenue	-526,000	-448,000	-515,000	-572,000	-571,000	-593,000	-1,200,000	-723,000	-766,000	-1,178,000	-2,260,000	-2,345,000	-1,685,000	-1,363,000	-2,145,000	-1,860,000	-1,144,000	-959,000	-1,354,000	-696,000	-689,000	-656,000	-677,000
non-cash interest expense	27,000	28,000	29,000	28,000	34,000	36,000	43,000	46,000	169,000	197,000	309,000	428,000	479,000	506,000	558,000	761,000	760,000	771,000	791,000	1,074,000	1,053,000	1,039,000	993,000
net accretion and amortization of investments in marketable securities	-668,000	-718,000	-923,000	-983,000	-676,000	-553,000	-619,000	-658,000	-534,000	-385,000	-224,000	-81,000	83,000	168,000	246,000	300,000	294,000	159,000	139,000	31,000	42,000	-2,000
net change in operating items:
accounts receivable	157,000	1,227,000	-801,000	159,000	372,000	-363,000	395,000	443,000	50,000	-1,312,000	483,000	135,000	-657,000	-414,000	768,000	-369,000	-33,000	47,000	-237,000	33,000	-36,000	132,000	1,184,000	-349,000	-1,116,000	508,000	-1,813,000	1,387,000	-286,000	-317,000	-325,000	-6,495,000	14,296,000	-7,605,000	674,000	177,000	-784,000	668,000	-3,419,000	5,785,000	1,148,000	-2,886,000	-35,000	-3,083,000	2,640,000	-1,409,000
prepaid expenses and other assets	-1,053,000	413,000	1,153,000	1,185,000	116,000	-156,000	1,097,000	-1,463,000	-109,000	-468,000	2,403,000	1,153,000	381,000	-1,507,000	-958,000	374,000	416,000	-857,000	-1,102,000	317,000	472,000	-439,000	526,000			2,110,000	-757,000	-113,000	-465,000	687,000	-916,000	92,000	255,000	-264,000	-699,000	1,157,000	-300,000	-273,000	-310,000	988,000	-740,000	221,000	-390,000	-626,000	-239,000	482,000
accounts payable and accrued liabilities	-7,601,000	4,545,000	20,000	-3,564,000	2,861,000	-2,024,000	465,000	1,001,000	-848,000	-6,376,000	3,760,000	-204,000	3,762,000	-2,102,000	1,326,000	1,167,000	2,214,000	-2,796,000	1,813,000	1,251,000	2,204,000	-3,602,000	-2,948,000	-350,000	3,634,000	-2,746,000	-2,360,000	173,000	5,108,000	-4,187,000	2,541,000	-4,010,000	6,114,000	-3,909,000	913,000	-929,000	1,158,000	-1,116,000	-4,897,000	9,759,000	-9,359,000	2,008,000	3,896,000	3,300,000	-1,994,000	1,051,000
change in deferred license revenue	-9,622,000	-812,000	-477,000	-123,000	-513,000	-244,000		-3,221,000
other liabilities	-121,000	-104,000	-124,000	-156,000	-78,000	-72,000	-155,000	-142,000	-73,000	-74,000	-124,000	-132,000	-74,000	-75,000		-125,000	-2,000	-116,000		-134,000	-20,000	-131,000	-219,000			-87,000
net cash from operating activities	-15,749,000	-13,391,000	-10,315,000	-20,736,000	-14,504,000	-19,295,000	-17,292,000	-21,784,000	-19,559,000	-27,301,000	-16,990,000	-18,692,000	-20,293,000	20,619,000	-19,606,000	-16,036,000	-14,009,000	-17,881,000	-15,013,000	-12,174,000	-8,801,000	-15,453,000	-47,536,000	-5,865,000	-1,025,000	-16,580,000	-54,662,000	4,418,000	2,345,000	-19,967,000	-32,960,000	-10,602,000	12,457,000	-17,535,000	-43,173,000	2,092,000	-5,258,000	-11,546,000			1,172,000	-17,843,000	-5,701,000	1,290,000	-17,165,000	9,155,000
capex	0	0	-86,000	0	-1,000	-95,000	0	-32,000	-859,000	-117,000	-134,000	-91,000	-212,000	-75,000	-58,000	-20,000	-632,000	-99,000	-152,000	-11,000	0	0	-334,000	-15,000	-209,000	-31,000	-901,000	188,000	-177,000	-248,000	-6,726,000	2,583,000	302,000	-3,423,000	-3,828,000	786,000	-678,000	-276,000			-242,000	-141,000	-904,000	94,000	89,000	-335,000
free cash flows	-15,749,000	-13,391,000	-10,401,000	-20,736,000	-14,505,000	-19,390,000	-17,292,000	-21,816,000	-20,418,000	-27,418,000	-17,124,000	-18,783,000	-20,505,000	20,544,000	-19,664,000	-16,056,000	-14,641,000	-17,980,000	-15,165,000	-12,185,000	-8,801,000	-15,453,000	-47,870,000	-5,880,000	-1,234,000	-16,611,000	-55,563,000	4,606,000	2,168,000	-20,215,000	-39,686,000	-8,019,000	12,759,000	-20,958,000	-47,001,000	2,878,000	-5,936,000	-11,822,000			930,000	-17,984,000	-6,605,000	1,384,000	-17,076,000	8,820,000
investing activities
purchase of investments in marketable securities	-28,498,000	-34,716,000	-43,191,000	-40,336,000	-32,585,000	-25,397,000	-24,019,000	-7,085,000	-29,200,000	-20,205,000
proceeds from sale of property and equipment							0					0													-7,000	9,000	0	23,000
disposition of investments in marketable securities	44,100,000	46,065,000	56,688,000	28,350,000	42,415,000	37,186,000	46,244,000	17,526,000	31,500,000	37,000,000
acquisition of property and equipment			-86,000	0	-1,000	-95,000	0	-32,000	-859,000	-117,000	-134,000	-91,000	-212,000	-75,000	-58,000	-20,000	-632,000	-99,000	-152,000	-11,000			-334,000	-15,000	-209,000	-31,000	-901,000	188,000	-177,000	-248,000	-6,726,000	2,583,000	302,000	-3,423,000	-3,828,000	786,000	-678,000	-276,000			-242,000	-141,000	-904,000	94,000	89,000	-335,000
net cash from investing activities	15,611,000	11,349,000	13,411,000	-11,986,000	9,829,000	11,694,000		10,429,000	1,441,000	16,678,000	12,682,000	-13,738,000	-13,830,000	-60,056,000	-8,121,000				-49,976,000	14,097,000																							-42,515,000	42,795,000	-42,903,000	-335,000
financing activities
issuance of common shares pursuant to the open market sale agreement			-1,000	0	22,359,000	21,765,000	3,852,000	1,396,000	4,742,000	19,862,000		8,973,000	0	268,000		44,736,000	4,274,000	26,419,000		48,760,000	5,045,000	12,315,000			229,000	2,248,000
issuance of common shares pursuant to exercise of stock options	453,000	2,653,000	1,422,000	1,590,000	2,011,000	2,454,000	1,000	0	0	259,000
issuance of common shares pursuant to espp	0	131,000										159,000	0	236,000		214,000	0	247,000
net cash from financing activities	453,000	2,784,000	1,421,000	1,775,000	24,370,000	24,430,000	3,807,000	1,681,000	4,742,000	20,417,000	11,084,000	9,132,000	113,000	11,485,000	59,121,000	46,952,000	4,289,000	26,874,000	20,210,000	49,096,000	4,959,000	12,481,000	18,908,000	16,070,000	-57,000	2,536,000	55,211,000	-300,000	-53,632,000	54,367,000	49,261,000	57,000	-350,000	354,000	12,562,000	-370,000	331,000	115,000	143,754,000	-844,000	-141,860,000	142,820,000	59,992,000	450,000	-59,055,000	59,289,000
effect of foreign exchange rate changes on cash and cash equivalents	21,000	4,000	-33,000	5,000	-8,000	-13,000	14,000	8,000	-1,000	4,000	-4,000						0	-44,000	112,000	0	-46,000	-10,000	92,000	-81,000	19,000	38,000		492,000	204,000	-565,000		502,000	401,000	424,000		-773,000	-3,057,000	3,006,000			3,401,000	-2,434,000	-1,216,000
increase in cash and cash equivalents	336,000	746,000				16,816,000				9,798,000				-27,952,000	31,399,000	46,929,000	-48,467,000	27,170,000	-44,667,000	51,019,000									39,563,000	-41,831,000	39,866,000	-3,348,000	-12,077,000	6,438,000	-127,026,000	85,462,000	-79,795,000	-22,007,000			-185,160,000	160,089,000	10,560,000	42,000,000	-114,730,000	65,640,000
cash and cash equivalents, beginning of period	0	36,330,000	0	0	0	26,285,000	0	0	0	30,776,000	0	0	0	109,282,000	0	0	0	52,251,000	0	0	0	31,799,000	-41,930,000						-41,831,000	54,292,000	-799,000	-5,639,000	6,438,000	23,413,000	123,809,000	-101,802,000	-22,007,000	166,779,000	-135,018,000	-25,071,000	160,089,000	72,187,000	-16,550,000	-49,090,000	65,640,000	68,717,000
cash and cash equivalents, end of period	336,000	37,076,000	4,484,000	-30,942,000	19,687,000	43,101,000	8,754,000	-9,666,000	-13,377,000	40,574,000	6,772,000	-23,316,000	-34,010,000	81,330,000	31,399,000	46,929,000	-48,467,000	79,421,000	-44,667,000	51,019,000	19,483,000	26,416,000	-58,283,000						-2,268,000	12,461,000	39,067,000	-8,987,000	-5,639,000	29,851,000	-3,217,000	-16,340,000	-101,802,000	144,772,000	-14,310,000	-26,116,000	-25,071,000	232,276,000	-5,990,000	-7,090,000	-49,090,000	134,357,000
loss on impairment of lab equipment			0
gain on sale of property and equipment							0					0													7,000	-9,000	0
issuance of common shares pursuant to exercise of espp					0	211,000	-46,000	285,000	0	296,000
increase / (decrease) in cash and cash equivalents																						-5,383,000
increase/(decrease) in cash and cash equivalents				-30,942,000
deferred license revenue										-4,104,000	-3,008,000	-2,352,000	-11,025,000	38,840,000
net cash provided by/(used in) investing activities
issuance of common shares pursuant to share purchase agreement											0	0	0	10,973,000
decrease in cash and cash equivalents							8,754,000	-9,666,000
issuance of common shares pursuant to the atm
supplemental cash flow information
preferred shares dividends accrued															-574,000	-5,087,000	-3,266,000	-3,212,000	-3,123,000	-3,027,000	-2,995,000	-2,978,000	-8,357,000	-5,554,000	47,000	2,715,000	7,524,000	26,000
purchase of investments												-32,647,000	-22,638,000	-61,981,000		-11,000	-52,115,000	-2,030,000		-2,992,000	-1,543,000	-24,369,000
disposition of investments												19,000,000	9,000,000	2,000,000		16,000,000	14,000,000	20,350,000		19,600,000	24,980,000	21,968,000
issuance of common shares pursuant to exercise of options												0	113,000	8,000	-115,000	2,002,000	15,000	208,000	33,000	336,000	-86,000	166,000			-286,000	288,000	947,000	-300,000	632,000	103,000	39,000	57,000	3,000	1,000	116,000	75,000	-114,000	115,000	1,535,000	-823,000	319,000	620,000	2,348,000	120,000	-1,776,000	1,924,000
(decrease)/increase in cash and cash equivalents
unrealized foreign exchange losses																	0	44,000		0	46,000	10,000
unrealized foreign exchange gains
net equity investment loss																			1,000
lease liabilities
investment in genevant																			0
issuance of common shares pursuant to exercise of espp options
issuance of common shares pursuant to the open market sales agreement
restructuring accrual
net cash (used) provided by investing activities
net cash provided (used) by investing activities																		18,221,000
deferred income tax benefit																							0				0
loss on sale of property and equipment
impairment of intangible assets																							0				0												1,017,000
impairment of goodwill																							0
proceeds from sale of future royalties
items not involving cash:
net equity investment gain
net cash from / (used in) investing activities																						-2,401,000
net income for the period																										-23,251,000			20,520,000	-17,429,000	-72,813,000	6,655,000	372,000	-18,627,000	-364,569,000	110,405,000	-114,126,000	-15,874,000			-2,897,000	-11,989,000
unrealized foreign exchange (gains) losses																									-19,000	-38,000		-492,000	-204,000	565,000		-504,000	-399,000	-425,000		775,000	3,057,000	-3,006,000			9,696,000	-7,057,000	-973,000	-4,636,000	1,450,000	-59,000
site consolidation non-cash portion
net change in non-cash operating items:
accrued revenue																																									2,430,000	-1,126,000	-399,000	-181,000	428,000	-208,000
investment tax credits receivable																										98,000				-2,000			309,000	-15,000
deferred revenue																											-2,417,000	421,000	276,000	-1,022,000	9,466,000	-6,086,000	-8,045,000	7,392,000	-370,000	-483,000	-56,000	-157,000	-16,101,000	2,677,000	1,625,000	-1,291,000	13,977,000	-1,261,000	-11,834,000	12,289,000
site consolidation accrual																									-501,000	-139,000	1,651,000	-381,000	-968,000	1,029,000
acquisition of investments																																											-41,691,000	42,701,000
proceeds from the sale of future royalties
promissory note repayment																														-12,001,000
proceeds from sale of preferred shares, net of issuance costs
issuance of common shares pursuant to open market sales agreement
initial investment in genevant
interest paid
gain on investment
equity investment loss																								178,000	-1,317,000	4,651,000	2,489,000
acquisition of short and long-term investments
disposition of short and long-term investments
net cash from (used) in investing activities																								6,183,000	-51,061,000	61,033,000		9,398,000	90,646,000	-75,666,000		6,695,000	-24,585,000	23,195,000		84,513,000	-71,811,000	-13,582,000			-47,873,000	37,546,000
proceeds from sale of series a preferred shares, net of issuance costs																														66,265,000
non-cash transactions:
net (loss)/income for the period
depreciation of property and equipment																									-4,000	509,000	1,684,000	-81,000	-24,000	602,000	1,434,000	113,000	146,000	334,000	801,000	39,000	35,000	217,000	436,000	6,000	27,000	120,000	396,000	-16,000	15,000	134,000
gain on equity investment
prepaid expenses and other current assets
other non-current liabilities
acquisition of short-term investments
disposition of short-term investments																									-50,845,000	61,055,000																37,363,000
increase in cash, cash equivalents, and restricted investment																									-52,124,000	47,027,000
cash, cash equivalents, and restricted investment, beginning of period																									47,027,000	36,942,000
cash, cash equivalents, and restricted investment, end of period																									-5,097,000	83,969,000
other assets																										167,000
stock-based compensation
change in fair value of warrant liability																																		22,000	-520,000	158,000	-7,000	-161,000			-3,247,000	1,223,000	5,243,000	10,953,000	-19,429,000	13,616,000
deferred rent and inducements
disposition (acquisition) of investments
issuance of common shares pursuant to exercise of warrants																																		353,000							-6,000	25,000	1,167,000	330,000	-802,000	888,000
effect of foreign currency rate changes on cash and cash equivalents
investment tax credits received
net (loss) for the period
stock-based compensation - research, development, collaborations and contract expenses																												-566,000	1,084,000	783,000	6,768,000	-587,000	433,000	2,622,000	8,396,000	240,000	-428,000	2,947,000	5,198,000	1,294,000	-780,000	2,157,000	2,017,000	-466,000	-56,000	848,000
stock-based compensation - general and administrative expenses																												-267,000	622,000	172,000	4,370,000	-537,000	167,000	1,881,000	26,309,000	-17,897,000	14,627,000	4,965,000	9,392,000	786,000	3,269,000	777,000	821,000	-170,000	-51,000	340,000
deferred lease incentives
disposition (acquisition) of short and long-term investments																												9,187,000	90,821,000	-75,418,000		4,112,000	-24,887,000	26,618,000		83,727,000	-71,133,000	-13,306,000
investment tax credit received																																0
acquired property and equipment in trade payables																																	-1,355,000	1,427,000
deferred income taxes
acquisition of restricted investment
cash acquired through acquisition
proceeds from loan payable
proceeds from issuance of common shares, net of issuance costs																																									-142,173,000	142,175,000				56,477,000
acquisition of property and equipment not yet paid
acquisition of arbutus inc. net of cash acquired
deferred expenses																																											111,000	-1,000	2,000	55,000
fair value of warrants exercised on a cashless basis
acquisition of arbutus inc. excluding cash acquired
cash acquired through acquisition of oncore																																										324,000
acquisition of oncore exclusing cash acquired																																										381,618,000
warrant issuance costs
fair value of warrants issued in conjunction with public offering
loss for the period																																												-2,523,000	11,903,000	-17,984,000
effect of foreign exchange rate changes on cash & cash equivalents																																													4,393,000	-2,469,000
income for the year
fair value of warrants issued in conjunction with debt facility
inventory
net cash (used in) operating activities
proceeds from issuance of common shares and warrants, net of issuance costs
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
foreign exchange (gains) losses arising on foreign currency cash balances
foreign exchange gains arising on foreign currency cash balances
proceeds from (acquisition of) short-term investments, ne

We provide you with 20 years of cash flow statements for Arbutus Biopharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Arbutus Biopharma stock. Explore the full financial landscape of Arbutus Biopharma stock with our expertly curated income statements.

The information provided in this report about Arbutus Biopharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.